Clinical Trial Update: Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma [Phase 4]

View source ↗

Summary

Phase 4 efficacy and safety study of 100 mg subcutaneous mepolizumab in Indian adults with severe eosinophilic asthma; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Nucala (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 4 | Status: COMPLETED | Results posted: 2024-12-10